论文部分内容阅读
以ＥＬＩＳＡ法检测３０例健康人和１０７例乙型肝炎和肝癌病人的血浆肿瘤坏死因子（ＴＮＦ）结果显示：健康人、急肝、慢迁肝、慢活肝、肝硬化和肝癌病人的ＴＮＦ分别为４．２７±２．１、２０．３±１１．２、７．７３±６．１７、３６．１±２９．５、８９．６±３０．４和３０．±２３．ｌｕｇ／ｍｌ，与健康人比较，除慢迁肝外，都有非常显著差异。慢迁肝、慢活肝和肝硬化病人的ＴＮＦ依次升高，在统计学上有显著差异。ＴＮＦ升高与ＡＬＴ，ＡＳＴ、ＨＢｅＡｇ、ｓＩＬ－２Ｒ密切相关，与ＩｇＧ、ＩｇＡ、ＩｇＭ无明显关系。２５例乙肝和１１例肝癌经用胸腺因子Ｄ等综合治疗后，除３例乙肝外，其余病例均在好转出院时血浆ＴＮＦ降至接近正常水平。但ＴＮＦ与慢重肝的预后并非一定相关。
The plasma tumor necrosis factor (TNF) of 30 healthy subjects and 107 patients with hepatitis B and liver cancer was detected by ELISA. The results showed that: TNF in healthy, acute liver, slow-moving liver, slow-moving liver, liver cirrhosis and liver cancer patients It is 4.27±2.1, 20.3±11.2, 7.73±6.17, 36.1±29.5, 89.6±30.4 and 30. ±23. Lug/ml, compared with healthy people, except for slow liver relocation, there are very significant differences. The TNF in patients with slow-moving liver, slow-moving liver, and cirrhosis increased in turn and there were statistically significant differences. The increase of TNF was closely related to ALT, AST, HBeAg, and sIL-2R, but not to IgG, IgA, IgM. After comprehensive treatment of 25 cases of hepatitis B and 11 cases of liver cancer with thymic factor D, except for 3 cases of hepatitis B, plasma TNF decreased to near normal levels in other cases after improvement. However, the prognosis of TNF and slow heavier liver is not necessarily related.